The aim of the present study was to assess the impact of MBS on major cardiovascular adverse events (MACE) in patients with severe obesity and T2D compared to patients with T2D treated with GLP-1 RA. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.